Healthesystems is attending the Colorado Workers' Compensation Education Conference for stakeholders in Colorado workers' comp.
Healthesystems is attending the California Division of Workers’ Compensation Annual Educational Conference for those who participate in the CA workers’ comp system.
Approval Date: Dec 2023
Indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily
Approval Date: Nov 2023
Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults, or overweight adults with at least one weight-related comorbidity
Approval Date: Nov 2023
Indicated as an adjunct to diet and exercise to improve glycemic control of type 2 diabetes
Approval Date: Nov 2023
Indicated for erosive esophagitis and the relief of heartburn associated with erosive esophagitis
Approval Date: Oct 2023
Indicated for the maintenance treatment of moderate to severe ulcerative colitis or moderate to severe Crohn’s disease, following treatment with an infliximab product administered intravenously
Approval Date: Oct 2023
A first-in-class agent indicated for the treatment of moderate to severe ulcerative colitis
Approval Date: Oct 2023
A biosimilar to Stelara, indicated for the treatment of moderate to severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis
Approval Date: Oct 2023
Indicated for the treatment of moderate to severe ulcerative colitis
Approval Date: Oct 2023
Indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and other autoimmune conditions, this drug is now available in an intravenous formulation
Approval Date: Oct 2023
Indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy